Not a good buy right now for an impatient trader: technical momentum is still bearish (negative, expanding MACD) and statistical next-day/week/month drift is biased lower.
Price is sitting just below/around first support (S1 ~2.624 vs pre-market ~2.6175), so a bounce is possible, but there is no proprietary buy signal and no near-term news catalyst.
Options positioning is very call-heavy (low put/call ratios), suggesting speculative bullish sentiment, but that alone doesn’t outweigh the bearish trend + deteriorating quarterly loss profile.
Technical Analysis
Trend/Momentum: MACD histogram is negative (-0.037) and negatively expanding → downside momentum still building.
RSI: RSI(6) at ~24 is effectively oversold, which can support a short-term bounce, but oversold can persist in downtrends.
Moving averages: converging MAs → compression/indecision; needs a clear reclaim of key levels to confirm reversal.
Key levels: Pivot 2.868 (major hurdle). Support S1 2.624 (being tested) then S2 2.474. Resistance R1 3.112 then R2 3.263.
Pattern/quant bias: Similar-pattern projection implies ~70% chance of -0.45% next day, -2.25% next week, -3.31% next month → favors patience/avoid chasing.
Positioning/Sentiment: Open interest put-call ratio 0.19 and volume put-call ratio 0.13 → heavily call-skewed, bullish/speculative sentiment.
Activity: Today’s option volume 1,131 with ~262% vs 30-day average → unusually elevated trading interest.
Volatility: 30D IV ~365% vs historical vol ~137% → extremely expensive options pricing; IV percentile ~36 suggests not at peak vs its own history, and IV is below the 5D avg (563) → volatility has been cooling recently.
Takeaway: Options market is betting on upside/bounce, but the underlying tape still shows bearish momentum; options enthusiasm may be speculation rather than confirmed trend reversal.
Technical Summary
Sell
8
Buy
6
Positive Catalysts
price near support (S1 ~2.
can trigger a reflex bounce if buyers defend the level.
Neutral/Negative Catalysts
Bearish momentum remains intact: MACD negative and expanding → trend pressure still down.
No news in the past week → lack of fresh catalysts to reverse sentiment immediately.
Similar-pattern probabilities point to continued drift lower across 1D/1W/1M horizons.
Extremely high implied volatility can amplify price swings and often reflects uncertainty rather than confirmed bullish fundamentals.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 0 (no meaningful operating revenue; typical for clinical-stage biotech).
Profitability: Net loss widened to -$7.26M (down 42.53% YoY), EPS -0.37 (down 61.86% YoY) → losses are growing rather than shrinking.
Growth trend takeaway: financial trajectory is deteriorating YoY on earnings metrics, increasing reliance on funding/catalysts rather than business momentum.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, so no confirmed recent Wall Street upgrades/downgrades can be summarized.
Wall Street-style pros (general biotech view): asymmetric upside if clinical/strategic catalysts land; options market currently reflects bullish speculation.
Wall Street-style cons: pre-revenue profile with worsening YoY loss metrics; without clear catalyst/news, the tape can stay weak and dilute/bearish pressure can dominate.
Influential/flow check: Hedge funds neutral, insiders neutral; no recent Congress trading data available.
Wall Street analysts forecast ANVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANVS is 12.5 USD with a low forecast of 8 USD and a high forecast of 17 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast ANVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANVS is 12.5 USD with a low forecast of 8 USD and a high forecast of 17 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.440
Low
8
Averages
12.5
High
17
Current: 2.440
Low
8
Averages
12.5
High
17
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$12 -> $10
AI Analysis
2025-09-03
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$12 -> $10
AI Analysis
2025-09-03
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Annovis Bio to $10 from $12 and keeps a Buy rating on the shares. The firm says the company's buntanetap Alzheimer's disease pivotal trial remains in progress. It cites a lengthier time to potential approval for the target cut.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$30 -> $12
2025-06-09
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$30 -> $12
2025-06-09
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Annovis Bio to $12 from $30 and keeps a Buy rating on the shares. The firm cites the impact of the most recent equity financing in February of this year, future potential equity issuances and the exercise of warrants for the target cut.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ANVS
